With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field
Gilead Sciences is turning to Nurix Therapeutics in an effort to discover new drugs that harness the cellular machinery our bodies use to dispose of damaged or harmful proteins.
Why Gilead could pay more than $2 billion in deal with this small S.F. biotech
Founded by three professors from UC Berkeley and UCSF, Nurix’s protein-degradation approach to cancer, and potentially other diseases, could stop cancer in its tracks.
The Differences Between Device and Drug Studies
Device and drug trials pose a variety of challenges; they are, after all, completely different in study design, have varying regulatory pathways, as well as differing executional challenges. In this interview, Tony Fiorino, Chief Medical Officer of electroCore, will discuss challenges he has faced with device studies, and will elaborate on his experiences about the differences between device and drug trials.
Arqule sees strength in early BTK inhibitor data; shares rise on phase I CLL news
Shares of Arqule Inc. (NASDAQ:ARQL) hit a 52-week high Friday on news that the company’s Bruton’s tyrosine kinase (BTK) inhibitor, ARQ-531, achieved partial responses in four of six heavily pretreated people with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) during an ongoing phase I trial.
Terumo plans to take Orchestra BioMed’s sirolimus balloon international in $35M deal
Orchestra BioMed is partnering up with Terumo to help develop and commercialize its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions. The Virtue angioplasty system is designed to deliver a bioabsorbable, sustained-release formulation of sirolimus directly into the artery wall. The drug helps prevent the vessel from narrowing and reclogging following the placement of a stent or other intervention, a process known as restenosis.
A CRISPR startup is testing pig organs in monkeys to see if they’re safe for us
Gene-editing company eGenesis is now carrying out experiments to help solve a critical shortage of human organs available for transplant.
CAR-T Therapy Development on the Rise
Now, the biotech company Celyad is looking for a non-gene-edited approach to create allogeneic CAR-T cells using RNAi. Last October, Celyad announced a collaboration with shRNA experts Dharmacon, a Horizon Discovery company, to use their optimized shRNA technology to create CAR-T therapies.
Arena Pharmaceuticals’ Selective CB2 Receptor Activator Drug Candidate Fights Pain in Irritable Bowel Syndrome
For about 12 percent of the world’s population living with the bowel movement disorder, irritable bowel syndrome, abdominal pain is a part of everyday life. While there are drugs available to treat symptoms like constipation and diarrhea, there is one complication that few irritable bowel syndrome drugs treat effectively. “What’s common to all irritable bowel syndrome patients is the presence of abdominal pain, and it is probably the aspect of the condition that is most difficult to treat,” said Dr. Preston Klassen, Head of Research and Development and Chief Medical Officer at Arena Pharmaceuticals.
